II期试验-话题@MedSci

#II期试验#

98篇内容 | 2628人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1947765, encodeId=09b5194e76509, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Ann Rheum Dis：托法替尼治疗强直性脊柱炎的III期试验结果, objectType=article, longId=214492, objectId=c20e21449280, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c20e21449280, replyNumber=0, likeNumber=94, createdTime=2021-10-16, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c20e21449280, moduleTitle=Ann Rheum Dis：托法替尼治疗强直性脊柱炎的III期试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c20e21449280)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947762, encodeId=acd3194e7622e, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Celltrion发布抗COVID-19单克隆抗体治疗瑞丹维单抗(CT-P59)全球III期试验的阳性顶线结果, objectType=article, longId=212850, objectId=8a1421285025, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a1421285025, replyNumber=0, likeNumber=73, createdTime=2021-07-08, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a1421285025, moduleTitle=Celltrion发布抗COVID-19单克隆抗体治疗瑞丹维单抗(CT-P59)全球III期试验的阳性顶线结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a1421285025)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947749, encodeId=e2b5194e7497e, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=美国**新冠疫苗临床试验揭盲，将开启终极3万人大规模III期试验, objectType=article, longId=197606, objectId=7ad819e606e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ad819e606e1, replyNumber=0, likeNumber=72, createdTime=2021-05-13, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ad819e606e1, moduleTitle=美国**新冠疫苗临床试验揭盲，将开启终极3万人大规模III期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ad819e606e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947746, encodeId=4834194e746d8, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Lancet oncol：III期试验：ripretinib单药治疗晚期胃肠间质肿瘤的疗效和安全性, objectType=article, longId=195474, objectId=2d9e1954e445, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d9e1954e445, replyNumber=0, likeNumber=77, createdTime=2020-08-22, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d9e1954e445, moduleTitle=Lancet oncol：III期试验：ripretinib单药治疗晚期胃肠间质肿瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d9e1954e445)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947747, encodeId=f804194e7478f, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Transplantation：肝源间充质干细胞在小儿肝脏代谢性疾病中的I/II期试验, objectType=article, longId=196792, objectId=b47f196e9205, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b47f196e9205, replyNumber=0, likeNumber=76, createdTime=2021-05-11, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b47f196e9205, moduleTitle=Transplantation：肝源间充质干细胞在小儿肝脏代谢性疾病中的I/II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b47f196e9205)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947745, encodeId=6a90194e745bf, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=抗体片段efgartigimod治疗重症肌无力：III期试验迎硕果！, objectType=article, longId=194860, objectId=254019486069, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=254019486069, replyNumber=0, likeNumber=77, createdTime=2020-11-07, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=254019486069, moduleTitle=抗体片段efgartigimod治疗重症肌无力：III期试验迎硕果！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=254019486069)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947754, encodeId=5686194e7540b, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=和记黄埔启动HMPL-453治疗晚期肝内胆管癌的II期试验, objectType=article, longId=200232, objectId=130b2002327c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=130b2002327c, replyNumber=0, likeNumber=58, createdTime=2020-09-23, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=130b2002327c, moduleTitle=和记黄埔启动HMPL-453治疗晚期肝内胆管癌的II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=130b2002327c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947751, encodeId=c271194e75160, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Relacorilant治疗库欣综合症：已开展III期试验, objectType=article, longId=198329, objectId=dfc319832925, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfc319832925, replyNumber=0, likeNumber=56, createdTime=2021-02-02, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfc319832925, moduleTitle=Relacorilant治疗库欣综合症：已开展III期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfc319832925)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947748, encodeId=6ea5194e74871, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Eur Urol：转移去势抵抗性前列腺癌男性双相雄激素治疗的多队列开放标签II期试验, objectType=article, longId=197385, objectId=1ef219e38501, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ef219e38501, replyNumber=0, likeNumber=105, createdTime=2020-09-04, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ef219e38501, moduleTitle=Eur Urol：转移去势抵抗性前列腺癌男性双相雄激素治疗的多队列开放标签II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ef219e38501)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947753, encodeId=4fdb194e75311, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=SLEEP 2020：AXS-12（reboxetine）治疗嗜睡症，II期试验结果即将揭晓, objectType=article, longId=200039, objectId=e77f200039b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e77f200039b3, replyNumber=0, likeNumber=91, createdTime=2021-06-14, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e77f200039b3, moduleTitle=SLEEP 2020：AXS-12（reboxetine）治疗嗜睡症，II期试验结果即将揭晓, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e77f200039b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947741, encodeId=4ceb194e74185, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=吉利德宣布开展remdesivir治疗中重度新冠病毒COVID-19患者的两项III期试验, objectType=article, longId=191476, objectId=71041914e630, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71041914e630, replyNumber=0, likeNumber=65, createdTime=2020-05-20, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71041914e630, moduleTitle=吉利德宣布开展remdesivir治疗中重度新冠病毒COVID-19患者的两项III期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71041914e630)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947743, encodeId=beaa194e74351, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Ann Rheum Dis：卡那单抗治疗成人Still病的II期试验, objectType=article, longId=194231, objectId=34331942313d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34331942313d, replyNumber=0, likeNumber=72, createdTime=2020-08-03, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34331942313d, moduleTitle=Ann Rheum Dis：卡那单抗治疗成人Still病的II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34331942313d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947752, encodeId=f1dd194e75279, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Leronlimab（PRO 140）治疗重度COVID-19：III期试验进展顺利, objectType=article, longId=199957, objectId=e37819995e34, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e37819995e34, replyNumber=0, likeNumber=53, createdTime=2021-02-20, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e37819995e34, moduleTitle=Leronlimab（PRO 140）治疗重度COVID-19：III期试验进展顺利, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e37819995e34)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947737, encodeId=3e3f194e737fe, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=难治性晚期或复发性卵巢癌患者的III期试验：Opdivo（Nivolumab）未能改善总生存率, objectType=article, longId=186740, objectId=76ac186e40ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76ac186e40ac, replyNumber=0, likeNumber=70, createdTime=2020-02-12, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76ac186e40ac, moduleTitle=难治性晚期或复发性卵巢癌患者的III期试验：Opdivo（Nivolumab）未能改善总生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76ac186e40ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947742, encodeId=b5d6194e742a7, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=失眠新药daridorexantIII期试验结果积极，显著改善睡眠质量, objectType=article, longId=192884, objectId=b6191928848c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6191928848c, replyNumber=0, likeNumber=122, createdTime=2020-06-07, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6191928848c, moduleTitle=失眠新药daridorexantIII期试验结果积极，显著改善睡眠质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6191928848c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947755, encodeId=718c194e75512, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始, objectType=article, longId=200275, objectId=54442002e505, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54442002e505, replyNumber=0, likeNumber=68, createdTime=2021-04-17, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54442002e505, moduleTitle=新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54442002e505)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947736, encodeId=329d194e73624, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=J Clin Oncol：III期试验：Ipilimumab辅助疗法与大剂量干扰素α-2b用于高风险黑色素瘤的优劣对比, objectType=article, longId=185702, objectId=43a9185e0237, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43a9185e0237, replyNumber=0, likeNumber=95, createdTime=2020-08-24, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43a9185e0237, moduleTitle=J Clin Oncol：III期试验：Ipilimumab辅助疗法与大剂量干扰素α-2b用于高风险黑色素瘤的优劣对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43a9185e0237)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947734, encodeId=f89f194e73498, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=痤疮治疗创新疗法Twyneo：达到了III期试验的主要终点, objectType=article, longId=185517, objectId=d8b718551ed7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8b718551ed7, replyNumber=0, likeNumber=71, createdTime=2020-06-25, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8b718551ed7, moduleTitle=痤疮治疗创新疗法Twyneo：达到了III期试验的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8b718551ed7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947730, encodeId=26eb194e73098, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Myovant口服促性腺激素释放激素拮抗剂relugolix的前列腺癌III期试验成功, objectType=article, longId=183428, objectId=910418342888, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=910418342888, replyNumber=0, likeNumber=61, createdTime=2020-05-23, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=910418342888, moduleTitle=Myovant口服促性腺激素释放激素拮抗剂relugolix的前列腺癌III期试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=910418342888)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1947750, encodeId=cb18194e75068, content=<a href='/topic/show?id=24ef96066d' target=_blank style='color:#2F92EE;'>#II期试验#</a>, objectTitle=Nat Med：III期试验发现，二甲双胍提高了接受过颅脑放疗儿童脑瘤患者的工作记忆和陈述记忆, objectType=article, longId=198304, objectId=78bd19830463, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78bd19830463, replyNumber=0, likeNumber=84, createdTime=2021-07-01, rootId=0, userName=ms5187542471278033, userId=ec952500165, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78bd19830463, moduleTitle=Nat Med：III期试验发现，二甲双胍提高了接受过颅脑放疗儿童脑瘤患者的工作记忆和陈述记忆, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78bd19830463)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期试验

2020-05-29

柳叶一刀 (审核中...)

前往app查看评论内容

#II期试验#

Ann Rheum Dis：托法替尼治疗强直性脊柱炎的III期试验结果

2021-10-16

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

Celltrion发布抗COVID-19单克隆抗体治疗瑞丹维单抗(CT-P59)全球III期试验的阳性顶线结果

2021-07-08

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

美国**新冠疫苗临床试验揭盲，将开启终极3万人大规模III期试验

2021-05-13

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

Lancet oncol：III期试验：ripretinib单药治疗晚期胃肠间质肿瘤的疗效和安全性

2020-08-22

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

Transplantation：肝源间充质干细胞在小儿肝脏代谢性疾病中的I/II期试验

2021-05-11

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

抗体片段efgartigimod治疗重症肌无力：III期试验迎硕果！

2020-11-07

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

和记黄埔启动HMPL-453治疗晚期肝内胆管癌的II期试验

2020-09-23

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

Relacorilant治疗库欣综合症：已开展III期试验

2021-02-02

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

Eur Urol：转移去势抵抗性前列腺癌男性双相雄激素治疗的多队列开放标签II期试验

2020-09-04

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

SLEEP 2020：AXS-12（reboxetine）治疗嗜睡症，II期试验结果即将揭晓

2021-06-14

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

吉利德宣布开展remdesivir治疗中重度新冠病毒COVID-19患者的两项III期试验

2020-05-20

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

Ann Rheum Dis：卡那单抗治疗成人Still病的II期试验

2020-08-03

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

Leronlimab（PRO 140）治疗重度COVID-19：III期试验进展顺利

2021-02-20

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

难治性晚期或复发性卵巢癌患者的III期试验：Opdivo（Nivolumab）未能改善总生存率

2020-02-12

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

失眠新药daridorexantIII期试验结果积极，显著改善睡眠质量

2020-06-07

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始

2021-04-17

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

J Clin Oncol：III期试验：Ipilimumab辅助疗法与大剂量干扰素α-2b用于高风险黑色素瘤的优劣对比

2020-08-24

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

痤疮治疗创新疗法Twyneo：达到了III期试验的主要终点

2020-06-25

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

Myovant口服促性腺激素释放激素拮抗剂relugolix的前列腺癌III期试验成功

2020-05-23

ms5187542471278033 (审核中...)

前往app查看评论内容

#II期试验#

Nat Med：III期试验发现，二甲双胍提高了接受过颅脑放疗儿童脑瘤患者的工作记忆和陈述记忆

2021-07-01

科室
- - 订阅+
  - 更多科室
工具
服务